Skin Cancer and Merkel Cell Carcinoma

View overview page
4:56
Nodal MCC with unknown primary site and no distant metastasis: a challenging entity
Nicola Fazio • 16 May 2023
0:26
Retifanlimab in Merkel cell carcinoma
Kari Kendra • 17 Apr 2023
1:20
Advances in immunotherapy for non-melanoma skin cancer
Paolo Ascierto • 12 Sep 2022
1:08
Novel approaches in treating Merkel cell carcinoma
Sungjune Kim • 11 Sep 2022
2:15
Incorporating immunotherapy and radiotherapy in Merkel cell carcinoma treatment regimens
Sungjune Kim • 11 Sep 2022
2:26
Nivolumab and ipilimumab in advanced Merkel cell carcinoma
Sungjune Kim • 11 Sep 2022
3:21
Unmet needs in nonmelanoma skin cancer
Dirk Schadendorf • 10 Sep 2022
0:44
Highlights in skin cancer at ESMO 2022
Dirk Schadendorf • 10 Sep 2022
1:27
MERKLIN 1: domatinostat + avelumab in MCC
Paolo Ascierto • 18 Sep 2021
2:59
Adjuvant and neoadjuvant immunotherapy in MCC
Paul Nghiem • 3 Jun 2021
2:05
Next steps in MCC: new targets and tacking PD-1 resistance
Paul Nghiem • 2 Jun 2021
2:38
Long-term follow-up results from JAVELIN Merkel 200 and KEYNOTE-017 in MCC
Paul Nghiem • 3 Jun 2021
3:43
Impact and role of radiotherapy in the management of MCC
Paul Nghiem • 14 Apr 2021
5:25
The current treatment landscape for MCC
Paul Nghiem • 14 Apr 2021
1:21
Treating PD-1/PD-L1 refractory MCC
Paul Nghiem • 14 Apr 2021
2:27
Serum NSE levels as a biomarker in MCC
Alexander van Akkooi • 19 Apr 2021
The content of VJOncology is intended for healthcare professionals